UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)


x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March 31,~~June 30, 2023


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission File Number: 001-39516

OWLET, INC.

(Exact Name of Registrant as Specified in its Charter)


Delaware			85-1615012
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
3300 North Ashton Boulevard, Suite 300 Lehi, Utah			84043
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: (844) 334-5330

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Class A Common Stock, $0.0001 par value per share

OWLT

~~New York Stock Exchange~~

~~Warrants to purchase Class A Common Stock~~

~~OWLT WS~~

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	x	Smaller reporting company	x
Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~May~~August 10, 2023, the registrant had ~~117,672,234~~8,477,224 shares of common stock, $0.0001 par value per share, outstanding.

Table of Contents


		Page

PART I.
	C a ~~utionary~~Cautionary Note Regarding ~~Forward-Looking~~Forward-Looking Statements	1
Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheets (Unaudited)	3
	Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)	4
	Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) (Unaudited)	5
	Condensed Consolidated Statements of Cash Flows (Unaudited)	67
	Notes to Condensed Consolidated Financial Statements (Unaudited)	78
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1820
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2527
Item 4.	Controls and Procedures	2628

PART II.
Item 1.	Legal Proceedings	2830
Item 1A.	Risk Factors	2830
Item 2.	Unregistered Sales of Equity Securities ~~and~~ , Use of Proceeds , and Issuer Purc hases of Equity Securities	2932
Item 3.	Defaults Upon Senior Securities	2932
Item 4.	Mine Safety Disclosures	2932
Item 5.	Other Information	2932
Item 6.	Exhibits	3034
	Signatures	3135

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “Report”) contains certain statements that are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). All statements other than statements of historical facts contained in this Report, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Report and are subject to a number of risks, uncertainties and assumptions described under the sections in this Report and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the "Form 10-K") entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in this Report and our Form 10-K. These forward-looking statements are subject to numerous risks, including, without limitation, the following:

• our limited operating history;

• our history of net losses and our ability to achieve or maintain profitability;

•the impact of the warning letter, dated October 1, 2021, from the United States Food and Drug Administration (the “FDA”), later corrected in an amendment to such letter dated October 5, 2021 (the letter and amendment collectively, the “Warning Letter”) the subsequent suspension of distribution of the Owlet Smart Sock (the “Smart Sock”) in the U.S. and our ability to obtain necessary marketing authorization for the medical device features of the Owlet Dream Sock (the “Dream Sock”) and the Smart Sock where required;

•our ability to implement processes, procedures and operations necessary to market and sell medical devices

•our ability to grow and manage growth profitably, which may be affected by, among other things, our capital resources, inflation, recession, competition and the impact of discretionary consumer spending, retail sector and demographic trends, employee availability and other economic, business and regulatory conditions;

•our ability to enhance future operating and financial results and continue as a going concern;

•our ability to obtain additional financing in the future;

•risks associated with our current loan and debt agreements, including compliance with debt covenants, restrictions on our access to capital, the impact of our overall debt levels and our ability to generate sufficient future cash flows from operations to meet our debt service obligations and operate our business;

•our business strategies and plans and our ability to pursue and implement our strategic initiatives, reduce costs and grow revenues, as well as innovate existing products, continue developing new products, meet evolving customer demands and adapt to changes in consumer preferences and retail trends;

•the regulatory pathway for our products and communications from regulators, including the FDA and similar regulators outside of the United States, as well as legal proceedings, regulatory disputes and governmental inquiries;

•our ability to acquire, defend and protect our intellectual property and satisfy regulatory requirements, including but not limited to laws and requirements concerning privacy and data protection, privacy or data breaches, data loss and other risks associated with our digital platform and technologies;

•any defects in new products or enhancements to existing products;

•our ability to obtain and maintain regulatory approval or certification for our products, and any related restrictions and limitations of any approved or certified product;

•expectations regarding developments with regulatory bodies, and the timeline for related submissions by us and decisions by the regulatory bodies and notified bodies (including UK approved bodies);

•our ability to hire, retain, manage and motivate employees, including key personnel;

•our ability to upgrade and maintain our information technology systems;

•changes in and our compliance with laws and regulations applicable to our business;

•our ability to maintain our listing on The New York Stock Exchange ("NYSE"); and

•the impact and disruption to our business, financial condition, results of operations, supply chain constraints and logistics due to economic and other conditions beyond our control, such as health epidemics or pandemics, macro-economic uncertainties, social unrest, hostilities, natural disasters or other catastrophic events.

These risks and other important factors, including those discussed in this Report, may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and

uncertainties. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included elsewhere in this Report are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements included elsewhere in this Report. In addition, even if our results of operations, financial condition and liquidity, and events in the industry in which we operate, are consistent with the forward-looking statements included elsewhere in this Report, they may not be predictive of results or developments in future periods.

Any forward-looking statement that we make in this Report speaks only as of the date of such statement. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this Report. For all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Reform Act.

As used in this Report, unless otherwise stated or the context otherwise requires: “we,” “us,” “our,” “Owlet,” the “Company,” and similar references refer to Owlet, Inc. and its subsidiaries, “common stock” refers to our Class A common ~~stock and “warrants” refers to our publicly traded warrants.~~stock.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Owlet, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

(unaudited)


Assets	Assets	March 31, 2023		December 31, 2022		Assets	June 30, 2023		December 31, 2022
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	24,765	$	11,231	Cash and cash equivalents	$	24,746	$	11,231
Accounts receivable, net of allowance for doubtful accounts of $2,948 and $3,013, respectively		15,395		15,958
Accounts receivable, net of allowance for doubtful accounts of $2,898 and $3,013, respectively						Accounts receivable, net of allowance for doubtful accounts of $2,898 and $3,013, respectively	12,978		15,958
Inventory	Inventory	14,744		18,515		Inventory	12,389		18,515
Prepaid expenses and other current assets	Prepaid expenses and other current assets	4,957		5,558		Prepaid expenses and other current assets	1,633		5,558
Total current assets	Total current assets	59,861		51,262		Total current assets	51,746		51,262
Property and equipment, net	Property and equipment, net	834		1,108		Property and equipment, net	609		1,108
Right of use assets, net	Right of use assets, net	1,928		2,260		Right of use assets, net	1,639		2,260
Intangible assets, net	Intangible assets, net	2,270		2,279		Intangible assets, net	2,253		2,279
Other assets	Other assets	1,035		1,195		Other assets	1,017		1,195
Total assets	Total assets	$	65,928	$	58,104	Total assets	$	57,264	$	58,104
Liabilities, Convertible Preferred Stock, and Stockholders’ Equity (Deficit)
Liabilities, Convertible Preferred Stock, and Stockholders’ Deficit						Liabilities, Convertible Preferred Stock, and Stockholders’ Deficit
Current liabilities:	Current liabilities:					Current liabilities:
Accounts payable	Accounts payable	$	30,841	$	30,432	Accounts payable	$	22,758	$	30,432
Accrued and other expenses	Accrued and other expenses	14,038		19,984		Accrued and other expenses	11,205		19,984
Current portion of deferred revenues	Current portion of deferred revenues	1,042		1,148		Current portion of deferred revenues	1,036		1,148
Line of credit	Line of credit	—		4,685		Line of credit	8,176		4,685
Current portion of long-term debt	Current portion of long-term debt	4,798		10,353		Current portion of long-term debt	5,204		10,353
Total current liabilities	Total current liabilities	50,719		66,602		Total current liabilities	48,379		66,602
Long-term debt, net	Long-term debt, net	3,500		—		Long-term debt, net	2,000		—
Noncurrent lease liabilities	Noncurrent lease liabilities	715		1,162		Noncurrent lease liabilities	265		1,162
Common stock warrant liabilities	Common stock warrant liabilities	24,945		724		Common stock warrant liabilities	26,574		724
Other long-term liabilities	Other long-term liabilities	2,007		251		Other long-term liabilities	1,769		251
Total liabilities	Total liabilities	81,886		68,739		Total liabilities	78,987		68,739
Commitments and contingencies (Note 5)	Commitments and contingencies (Note 5)					Commitments and contingencies (Note 5)
Series A convertible preferred stock, 0.0001 par value, 100,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 30,000 and 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively (liquidation preference of $30,000)		4,520		—
Series A convertible preferred stock, $0.0001 par value, 10,741,071 shares authorized as of June 30, 2023 and December 31, 2022; 30,000 and 0 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively (liquidation preference of $30,000)						Series A convertible preferred stock, $0.0001 par value, 10,741,071 shares authorized as of June 30, 2023 and December 31, 2022; 30,000 and 0 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively (liquidation preference of $30,000)	5,593		—
Stockholders’ equity (deficit):	Stockholders’ equity (deficit):					Stockholders’ equity (deficit):
Common stock, $0.0001 par value, 1,000,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 117,465,938 and 115,388,135 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively.		12		12
Common stock, $0.0001 par value, 107,142,857 shares authorized as of June 30, 2023 and December 31, 2022; 8,441,683 and 8,242,009 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively.						Common stock, $0.0001 par value, 107,142,857 shares authorized as of June 30, 2023 and December 31, 2022; 8,441,683 and 8,242,009 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively.	1		1
Additional paid-in capital	Additional paid-in capital	214,135		212,111		Additional paid-in capital	215,775		212,122
Accumulated deficit	Accumulated deficit	(234,625)		(222,758)		Accumulated deficit	(243,092)		(222,758)
Total stockholders’ equity (deficit)		(20,478)		(10,635)
Total liabilities, convertible preferred stock, and stockholders’ equity (deficit)		$	65,928	$	58,104
Total stockholders’ deficit						Total stockholders’ deficit	(27,316)		(10,635)
Total liabilities, convertible preferred stock, and stockholders’ deficit						Total liabilities, convertible preferred stock, and stockholders’ deficit	$	57,264	$	58,104

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Owlet, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

(unaudited)


		For the Three Months Ended March 31,					Three Months Ended June 30,				Six Months Ended June 30,
		2023		2022			2023		2022		2023		2022
Revenues	Revenues	$	10,736	$	21,538	Revenues	$	13,088	$	18,348	$	23,824	$	39,887
Cost of revenues	Cost of revenues	6,583		12,782		Cost of revenues	7,855		11,726		14,438		24,507
Gross profit	Gross profit	4,153		8,756		Gross profit	5,233		6,622		9,386		15,380
Operating expenses:	Operating expenses:					Operating expenses:
General and administrative	General and administrative	8,866		10,276		General and administrative	6,124		9,492		14,990		19,769
Sales and marketing	Sales and marketing	3,353		11,631		Sales and marketing	3,078		9,723		6,431		21,354
Research and development	Research and development	2,890		8,545		Research and development	2,745		7,770		5,635		16,315
Total operating expenses	Total operating expenses	15,109		30,452		Total operating expenses	11,947		26,985		27,056		57,438
Operating loss	Operating loss	(10,956)		(21,696)		Operating loss	(6,714)		(20,363)		(17,670)		(42,058)
Other income (expense):
Other (expense) income:						Other (expense) income:
Interest expense, net	Interest expense, net	(2,812)		(226)		Interest expense, net	(52)		(203)		(2,864)		(429)
Common stock warrant liability adjustment	Common stock warrant liability adjustment	1,912		(6,876)		Common stock warrant liability adjustment	(1,629)		8,811		283		1,935
Other income (expense), net		(11)		47
Total other income (expense), net		(911)		(7,055)
Other (expense) income, net						Other (expense) income, net	(67)		63		(78)		109
Total other (expense) income, net						Total other (expense) income, net	(1,748)		8,671		(2,659)		1,615
Loss before income tax provision	Loss before income tax provision	(11,867)		(28,751)		Loss before income tax provision	(8,462)		(11,692)		(20,329)		(40,443)
Income tax provision	Income tax provision	—		(7)		Income tax provision	(5)		(26)		(5)		(33)
Net loss and comprehensive loss	Net loss and comprehensive loss	(11,867)		(28,758)		Net loss and comprehensive loss	(8,467)		(11,718)		(20,334)		(40,476)
Accretion on Series A convertible preferred stock	Accretion on Series A convertible preferred stock	(653)		—		Accretion on Series A convertible preferred stock	(1,326)		—		(1,979)		—
Net loss attributable to common stockholders	Net loss attributable to common stockholders	$	(12,520)	$	(28,758)	Net loss attributable to common stockholders	$	(9,793)	$	(11,718)	$	(22,313)	$	(40,476)
Net loss per share attributable to common stockholders, basic and diluted	Net loss per share attributable to common stockholders, basic and diluted	$	(0.11)	$	(0.26)	Net loss per share attributable to common stockholders, basic and diluted	$	(1.19)	$	(1.48)	$	(2.73)	$	(5.12)
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted	Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted	113,545,429		110,384,313		Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted	8,213,247		7,915,156		8,162,102		7,899,959

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Owlet, Inc.

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(in thousands, except share and per share amounts)

(unaudited)

Series A Convertible Preferred Stock Common Stock
Shares Amount Shares Amount Additional Paid-in
Capital Accumulated
Deficit Total Stockholders'
Equity (Deficit)
Balance as of December 31, 2021 — $ — 112,996,568 $ 11 $ 198,602 $ (143,422) $ 55,191
Issuance of common stock upon exercise of stock options — — 88,808 — 48 — 48
Issuance of common stock for restricted stock units vesting — — 321,098 — — — —
Share-based compensation — — — — 3,336 — 3,336
Net loss — — — — — (28,758) (28,758)
Balance as of March 31, 2022 — $ — 113,406,474 $ 11 $ 201,986 $ (172,180) $ 29,817
Balance as of December 31, 2022 — $ — 115,388,135 $ 12 $ 212,111 $ (222,758) $ (10,635)
Issuance of Series A convertible preferred stock 30,000 3,867 — — — — —
Preferred stock issuance costs — — — — (311) — (311)
Accretion on Series A convertible preferred stock — 653 — — (653) — (653)
Issuance of SVB Warrants (Note 4) — — — — 43 — 43
Issuance of common stock upon exercise of stock options — — 252,757 — 55 — 55
Issuance of common stock for restricted stock units vesting — — 1,613,578 — — — —
Issuance of common stock for employee stock purchase plan — — 211,468 — 101 — 101
Share-based compensation — — — — 2,789 — 2,789
Net loss — — — — — (11,867) (11,867)
Balance as of March 31, 2023 30,000 $ 4,520 117,465,938 $ 12 $ 214,135 $ (234,625) $ (20,478)


	Series A Convertible Preferred Stock			Common Stock
	Shares	Amount		Shares	Amount		Additional Paid-in Capital		Accumulated Deficit		Total Stockholders' Equity (Deficit)
Balance as of December 31, 2021	—	$	—	8,071,183	$	1	$	198,612	$	(143,422)	$	55,191
Issuance of common stock upon exercise of stock options	—	—		6,343	—		48		—		48
Issuance of common stock for restricted stock units vesting	—	—		22,935	—		—		—		—
Share-based compensation	—	—		—	—		3,336		—		3,336
Net loss	—	—		—	—		—		(28,758)		(28,758)
Balance as of March 31, 2022	—	$	—	8,100,461	$	1	$	201,996	$	(172,180)	$	29,817
Issuance of common stock upon exercise of stock options	—	—		29,866	—		166		—		166
Issuance of common stock for restricted stock units vesting	—	—		16,454	—		—		—		—
Share-based compensation	—	—		—	—		3,273		—		3,273
Net loss	—	—		—	—		—		(11,718)		(11,718)
Balance as of June 30, 2022	—	$	—	8,146,781	$	1	$	205,435	$	(183,898)	$	21,538

Owlet, Inc.

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) (Continued)

(in thousands, except share and per share amounts)

(unaudited)


	Series A Convertible Preferred Stock		Common Stock
	Shares	Amount	Shares	Amount	Additional Paid-in Capital	Accumulated Deficit		Total Stockholders' Equity (Deficit)
Balance as of December 31, 2022	—	—	8,242,009	1	212,122	(222,758)		(10,635)
Issuance of Series A convertible preferred stock	30,000	3,867	—	—	—	—		—
Preferred stock issuance costs	—	(253)	—	—	—	—		—
Accretion on Series A convertible preferred stock	—	653	—	—	(653)	—		(653)
Issuance of SVB Warrants (Note 4)	—	—	—	—	43	—		43
Issuance of common stock upon exercise of stock options	—	—	18,054	—	55	—		55
Issuance of common stock for restricted stock units vesting	—	—	115,257	—	—	—		—
Issuance of common stock for employee stock purchase plan	—	—	15,104	—	101	—		101
Share-based compensation	—	—	—	—	2,789	—		2,789
Net loss	—	—	—	—	—	(11,867)		(11,867)
Balance as of March 31, 2023	30,000	4,267	8,390,424	1	214,457	(234,625)		(20,167)
Accretion on Series A convertible preferred stock	—	1,326	—	—	(1,326)	—		(1,326)
Issuance of common stock for restricted stock units vesting	—	—	51,259	—	—	—		—
Share-based compensation	—	—	—	—	2,644	—		2,644
Net loss	—	—	—	—	—	(8,467)		(8,467)
Balance as of June 30, 2023	30,000	5,593	8,441,683	1	215,775	$	(243,092)	$	(27,316)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Owlet, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)


		For the Three Months Ended March 31,					Six Months Ended June 30,
		2023		2022			2023		2022
Cash flows from operating activities:
Cash flows from operating activities						Cash flows from operating activities
Net loss	Net loss	$	(11,867)	$	(28,758)	Net loss	$	(20,334)	$	(40,476)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:						Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	Depreciation and amortization	293		348		Depreciation and amortization	530		707
Share-based compensation	Share-based compensation	2,789		3,318		Share-based compensation	5,433		6,575
Common stock warrant liability adjustment	Common stock warrant liability adjustment	(1,912)		6,876		Common stock warrant liability adjustment	(283)		(1,935)
Amortization of right of use assets	Amortization of right of use assets	332		276		Amortization of right of use assets	667		602
Other adjustments, net	Other adjustments, net	177		358		Other adjustments, net	94		512
Changes in assets and liabilities:	Changes in assets and liabilities:					Changes in assets and liabilities:
Accounts receivable	Accounts receivable	480		(6,191)		Accounts receivable	2,925		(13,922)
Prepaid expenses and other assets	Prepaid expenses and other assets	1,261		5,512		Prepaid expenses and other assets	4,103		8,756
Inventory	Inventory	3,771		(6,733)		Inventory	6,222		(11,392)
Accounts payable and accrued and other expenses	Accounts payable and accrued and other expenses	(5,661)		(1,830)		Accounts payable and accrued and other expenses	(16,134)		(4,499)
Other, net	Other, net	963		(572)		Other, net	20		(588)
Net cash used in operating activities	Net cash used in operating activities	(9,374)		(27,396)		Net cash used in operating activities	(16,757)		(55,660)
Cash flows from investing activities	Cash flows from investing activities					Cash flows from investing activities
Purchase of property and equipment	Purchase of property and equipment	(6)		(234)		Purchase of property and equipment	(6)		(419)
Purchase of intangible assets	Purchase of intangible assets	(2)		(466)		Purchase of intangible assets	(13)		(824)
Net cash used in investing activities	Net cash used in investing activities	(8)		(700)		Net cash used in investing activities	(19)		(1,243)
Cash flows from financing activities	Cash flows from financing activities					Cash flows from financing activities
Proceeds from issuance of preferred stock		30,000		—
Proceeds from issuance of preferred stock, net of $295 of paid transaction costs						Proceeds from issuance of preferred stock, net of $295 of paid transaction costs	29,793		—
Proceeds from short-term borrowings	Proceeds from short-term borrowings	32,895		16,744		Proceeds from short-term borrowings	52,531		22,583
Payments of short-term borrowings	Payments of short-term borrowings	(38,635)		(13,514)		Payments of short-term borrowings	(51,189)		(20,693)
Proceeds from long-term borrowings						Proceeds from long-term borrowings	500		—
Payments of long-term borrowings	Payments of long-term borrowings	(1,500)		(1,500)		Payments of long-term borrowings	(1,500)		(3,000)
Other, net	Other, net	156		49		Other, net	156		215
Net cash provided by financing activities		22,916		1,779
Net cash provided by (used in) financing activities						Net cash provided by (used in) financing activities	30,291		(895)
Net change in cash and cash equivalents	Net change in cash and cash equivalents	13,534		(26,317)		Net change in cash and cash equivalents	13,515		(57,798)
Cash and cash equivalents at beginning of period	Cash and cash equivalents at beginning of period	11,231		95,054		Cash and cash equivalents at beginning of period	11,231		95,054
Cash and cash equivalents at end of period	Cash and cash equivalents at end of period	$	24,765	$	68,737	Cash and cash equivalents at end of period	$	24,746	$	37,256

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Owlet, Inc.

Notes to Condensed Consolidated Financial Statements

(in thousands, except share and per share amounts)

(unaudited)

Note 1. Basis of Presentation

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and applicable rules and regulations of the U.S. Securities and Exchange Commission (the "SEC") regarding interim financial reporting. The condensed consolidated balance sheet as of December 31, 2022, included herein, was derived from the audited consolidated financial statements as of that date, but does not include all disclosures including certain notes required by U.S. GAAP on an annual reporting basis. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary for the fair statement of the Company’s financial position, results of operations, and cash flows for the interim periods presented. All dollar amounts, except per share amounts, in the notes are presented in thousands, unless otherwise specified.

Certain prior year amounts have been reclassified to conform to the current period presentation.

Reverse Stock Split

On July 7, 2023, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect a one-for-14 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock and a reduction in the number of authorized shares of common stock and authorized but unissued shares of the Company’s preferred stock. The number of authorized shares of Common Stock was reduced from 1,000,000,000 shares to 107,142,857 shares, which reflects a reduction to 1.5 times the then current number of authorized shares of Common Stock, divided by the Reverse Stock Split ratio. The Reverse Stock Split also reduced the number of authorized shares of preferred stock from 100,000,000 shares to 10,741,071 shares, which reflects a reduction to 1.5 times the then current number of authorized but unissued shares of preferred stock, divided by the Reverse Stock Split ratio. The Reverse Stock Split became effective on July 7, 2023.

There was no net effect on total stockholders' equity, and the par value per share of our common stock remains unchanged at $0.0001 per share after the Reverse Stock Split. All references made to share or per share amounts in the accompanying condensed consolidated financial statements and applicable disclosures have been retroactively adjusted for all periods presented to reflect the applicable effects of the Reverse Stock Split and the reduction in the number of authorized shares of common stock and preferred stock effected by the Charter Amendment.

Risks and Uncertainties

In accordance with ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.

Since inception, the Company has experienced recurring operating losses and generated negative cash flows from operations, resulting in an accumulated deficit of ~~$234,625~~$243,092 as of ~~March 31,~~June 30, 2023. During the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022, we had negative cash flows from operations of ~~$9,374~~$16,757 and ~~$27,396,~~$55,660, respectively. As of ~~March 31,~~June 30, 2023, we had ~~$24,765~~$24,746 of cash on hand.

Year over year declines in revenue, the low, current cash balance, recurring operating losses, and negative cash flows from operations since inception raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the accompanying condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements have been prepared on a going concern basis and accordingly, do not include any adjustments relating to the recoverability and classification of asset carrying amounts, or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.

As the Company continues to address these financial conditions, management has undertaken the following actions:

•As described further in Note 7, on February 17, 2023 the Company consummated a sale of newly issued preferred stock and warrants to purchase its common stock for aggregate gross proceeds of $30,000.

•As described in Note 4, in March 2023 the Company further amended its financing arrangement with SVB, under which the principal payments on the term note will be deferred until September 2023. This most recent amendment also revised the financial covenants for future periods.

•During the year ended December 31, 2022, the Company undertook restructuring actions, which significantly reduced employee headcount and reduced operating spend. This included the reduction of consulting and outside services, the reduction of marketing programs, and the prioritization of and sequencing of research and development projects.

We have not generated sufficient cash flows from operations to satisfy our capital requirements. There can be no assurance that the Company will generate sufficient future cash flows from operations due to potential factors, including but not limited to inflation, recession, reduced demand for the Company’s products, or the FDA's denial of the Company's de novo classification request for marketing authorization. If revenues further decrease from current levels, the Company may be unable to further reduce costs, or such reductions may limit our ability to pursue strategic initiatives and grow revenues in the future.

There can be no assurance that we will be able to obtain additional financing on terms acceptable to us, if at all. Failure to secure additional funding may require us to modify, delay or abandon some of our planned future development, or to otherwise enact further operating cost reductions, which could have a material adverse effect on our business, operating results, financial condition and ability to achieve our intended business objectives.

If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to pursue our business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited, and our business, financial condition and results of operations could be materially adversely affected. We also could be required to seek funds through arrangements with partners or others that may require us to relinquish rights or jointly own some aspects of our technologies, products or services that we would otherwise pursue on our own.

The Company maintains its cash in bank deposit accounts which, at times, exceed federally insured limits. As of ~~March 31,~~June 30, 2023, substantially all of the Company's cash was held with Silicon Valley Bank and Citibank, and exceeded federally insured limits. On March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. On March 12, 2023, the Secretary of the Treasury, the chair of the Federal Reserve Board and the chairman of the FDIC released a joint statement related to the FDIC's resolution of the Silicon Valley Bank receivership, which provided that all depositors would have access to all their money starting March 13, 2023. As of the issuance date of these financial statements, all cash deposited by the Company with Silicon Valley Bank, now a division of First Citizens Bank and Trust Company, has been accessible by the Company.

Note 2. Certain Balance Sheet Accounts

Inventory

Substantially all of the Company's inventory consisted of finished goods as of ~~March 31,~~June 30, 2023 and December 31, 2022.

Property and Equipment, net

Property and equipment consisted of the following as of:


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Tooling and manufacturing equipment	Tooling and manufacturing equipment	$	2,731	$	2,731	Tooling and manufacturing equipment	$	2,731	$	2,731
Furniture and fixtures	Furniture and fixtures	639		639		Furniture and fixtures	639		639
Computer equipment	Computer equipment	640		660		Computer equipment	601		660
Software	Software	106		106		Software	106		106
Leasehold improvements	Leasehold improvements	35		29		Leasehold improvements	35		29
Total property and equipment	Total property and equipment	4,151		4,165		Total property and equipment	4,112		4,165
Less accumulated depreciation and amortization	Less accumulated depreciation and amortization	(3,317)		(3,057)		Less accumulated depreciation and amortization	(3,503)		(3,057)
Property and equipment, net	Property and equipment, net	$	834	$	1,108	Property and equipment, net	$	609	$	1,108

Depreciation and amortization expense on property and equipment was ~~$274~~$225 and ~~$309~~$320 for the three months ended ~~March 31,~~June 30, 2023 and ~~March 31,~~June 30, 2022, respectively. For the three months ended ~~March 31,~~June 30, 2023 and ~~March 31,~~June 30, 2022, the Company allocated ~~$182~~$148 and ~~$190,~~$208, respectively, of depreciation and amortization expense related to tooling and manufacturing equipment and software to cost of revenues.

Depreciation and amortization expense on property and equipment was $500 and $629 for the six months ended June 30, 2023 and June 30, 2022, respectively. For the six months ended June 30, 2023 and June 30, 2022, the Company allocated $330 and $398, respectively, of depreciation and amortization expense related to tooling and manufacturing equipment and software to cost of revenues.

Intangible Assets Subject to Amortization

Intangible assets were ~~$2,270,~~$2,253, net of accumulated amortization of ~~$225~~$236 as of ~~March 31,~~June 30, 2023 and $2,279, net of accumulated amortization of $206, as of December 31, 2022.

Capitalized software development costs were $1,873 on ~~March 31,~~June 30, 2023 and December 31, 2022. The Company's internally developed software capitalized within intangible assets on the balance sheet is still in development and not ready for general release. As such, the Company has not recognized any amortization for the three or six months ended ~~March 31,~~June 30, 2023 or 2022.

The Company did not recognize any impairment charges for intangible assets during the three or six months ended ~~March 31,~~June 30, 2023 or 2022.

Accrued and Other Expenses

On October 1, 2021, the Company received a Warning Letter, later corrected in an amendment to the letter dated October 5, 2021 (the “Warning Letter”), from the U.S. Food and Drug Administration (the “FDA”) regarding the Owlet Smart Sock. During the fourth quarter of 2021, the Company agreed with certain customers and retailers to accept returns of the Owlet Smart Sock and Owlet Monitor Duo.

Accrued and other expenses, among other things, included accrued sales returns of ~~$4,727~~$1,717 and $6,756 as of ~~March 31,~~June 30, 2023 and December 31, 2022, respectively. Accrued sales returns included ~~$3,407~~$36 and $4,958 as of ~~March 31,~~June 30, 2023 and December 31, 2022, respectively, for product returns related to the Warning Letter.

Changes in accrued warranty were as follows:


		For the Three Months Ended March 31,					For the Three Months Ended June 30,
		2023		2022			2023		2022
Accrued warranty, beginning of period	Accrued warranty, beginning of period	$	712	$	661	Accrued warranty, beginning of period	$	592	$	725
Provision for warranties issued during the period	Provision for warranties issued during the period	35		200		Provision for warranties issued during the period	81		193
Settlements of warranty claims during the period	Settlements of warranty claims during the period	(155)		(136)		Settlements of warranty claims during the period	(82)		(143)
Accrued warranty, end of period	Accrued warranty, end of period	$	592	$	725	Accrued warranty, end of period	$	591	$	775

~~Stockholders' Equity~~


	For the Six Months Ended June 30,
	2023		2022
Accrued warranty, beginning of period	$	712	$	661
Provision for warranties issued during the period	116		394
Settlements of warranty claims during the period	(237)		(280)
Accrued warranty, end of period	$	591	$	775

The Company is authorized to issue up to 100,000,000 shares of $0.0001 par value preferred stock, of which 30,000 and 0 shares were outstanding as of March 31, 2023 and December 31, 2022, respectively.

Note 3. Deferred Revenues

Deferred revenues relate to performance obligations for which payments are received from customers prior to the satisfaction of the Company’s obligations to its customers. Deferred revenues primarily consist of amounts allocated to the mobile application, unspecified upgrade rights, and content, and are recognized over the service period of the performance obligations, which range from 5 to 27 months.

Changes in the total deferred revenues balance were as follows:


		For the Three Months Ended March 31,					Three Months Ended June 30,				Six Months Ended June 30,
		2023		2022			2023		2022		2023		2022
Beginning balance	Beginning balance	$	1,386	$	1,235	Beginning balance	$	1,257	$	1,312	$	1,386	$	1,235
Deferral of revenues	Deferral of revenues	395		744		Deferral of revenues	480		687		820		1,430
Recognition of deferred revenues	Recognition of deferred revenues	(524)		(667)		Recognition of deferred revenues	(514)		(620)		(983)		(1,286)
Ending balance	Ending balance	$	1,257	$	1,312	Ending balance	$	1,223	$	1,379	$	1,223	$	1,379

The Company recognized ~~$483~~$456 and ~~$550~~$498 of revenue during the three months ended ~~March 31,~~June 30, 2023 and 2022, respectively, that was included in the deferred revenue balance at the beginning of the respective period. The Company recognized $797 and $838 of revenue during the six months ended June 30, 2023 and 2022, respectively, that was included in the deferred revenue balance at the beginning of the respective period.

Note 4. Long-Term Debt and Other Financing Arrangements

The following is a summary of the Company’s long-term indebtedness as of:


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Term note payable to SVB, maturing on October 1, 2024	Term note payable to SVB, maturing on October 1, 2024	$	7,000	$	8,000	Term note payable to SVB, maturing on October 1, 2024	$	7,000	$	8,000
Financed insurance premium	Financed insurance premium	1,298		2,353		Financed insurance premium	204		2,353
Total debt	Total debt	8,298		10,353		Total debt	7,204		10,353
Less: current portion	Less: current portion	(4,798)		(10,353)		Less: current portion	(5,204)		(10,353)
Total long-term debt, net	Total long-term debt, net	$	3,500	$	—	Total long-term debt, net	$	2,000	$	—

Third Amended and Restated Loan and Security Agreement

On November 23, 2022, the Company entered into the Third Amended and Restated Loan and Security Agreement (the “LSA”) with Silicon Valley Bank. The LSA amended, restated and replaced in its entirety the prior Second Amended and Restated Loan and Security Agreement, dated April 22, 2020, and all prior amendments. On March 27, 2023, the Company entered into the first amendment to the LSA with Silicon Valley Bank, now a division of First Citizens Bank and Trust Company (the “SVB Amendment”), that (i) deferred certain payments of principal by the Company until September 1, 2023, (ii) had Silicon Valley Bank waive certain stated events of default, (iii) to expand the eligibility of inventory and accounts that the Company can borrow against, (iv) to modify certain financial covenants required of the Company, and (v) certain other ~~revisions in the first amendment.~~revisions.

In connection with the amendment to the LSA executed on March 27, 2023, the Company granted Silicon Valley Bank a warrant to purchase ~~150,000~~10,714 shares of the Company's common stock at a price of ~~$0.38~~$5.32 per share, expiring on

March 27, 2035 (the "SVB Warrants"). The warrant was valued at $43 and is classified as equity and included within additional paid-in capital on the condensed consolidated balance sheet. See Note 7 for a summary of all common stock warrants currently outstanding.

On August 10, 2023, the Company entered into the second amendment to the LSA with Silicon Valley Bank, now a division of First Citizens Bank and Trust Company, that clarified the calculation of the financial covenants under the agreement.

As of the date of this Report, the Company was in compliance with all applicable covenants under the LSA.

Line of Credit

The LSA provides for a $10,000 revolving line of credit (the “SVB Revolver”) as of ~~March 31,~~June 30, 2023. The SVB Revolver is an ~~asset based~~asset-based lending facility subject to borrowing base availability, which is limited by specified percentages of eligible accounts receivable and eligible inventory. Borrowing base availability can be impacted based upon the period's eligible accounts receivable and eligible inventory and may be significantly lower than the full $10,000 line of credit. As of ~~March 31,~~June 30, 2023, borrowing base availability was ~~$7,086.~~$8,364.

The SVB Revolver facility matures and terminates on April 22, 2024. As of ~~March 31,~~June 30, 2023, the SVB Revolver bore interest on the outstanding principal amount at a floating rate per annum equal to the greater of (i) 5.00% and (ii) the prime rate plus the prime rate margin, which is 2.25% for advances on the SVB Revolver, as defined by the LSA. As of ~~March 31,~~June 30, 2023 there ~~were no~~was $8,176 of outstanding borrowings under the SVB Revolver.

Term Loan

The LSA also provided for an $8,500 term loan (the “Term Loan”), replacing the term loans made under the previous agreement, of which $7,000 was outstanding as of ~~March 31,~~June 30, 2023. The Term Loan amortizes with equal monthly installments of $500 and matures on October 1, ~~2024.~~2024 (the "Term Loan Maturity Date").

The Term Loan accrues interest on the outstanding principal amount at a floating rate per annum equal to the greater of (i) five and three-quarters percent (5.75%) and (ii) the prime rate plus the prime rate margin, which is 3.50% for the Term Loan (as defined in the LSA), and such interest is payable (a) monthly in arrears, (b) on each prepayment date and (c) on the Term Loan Maturity Date. All outstanding principal and accrued and unpaid interest and all other Term Loan-related outstanding obligations shall become due and payable in full on the Term Loan ~~maturity date.~~Maturity Date.

The Company believes that the fair value of the Term Loan approximates the recorded amount as of ~~March 31,~~June 30, 2023 and December 31, 2022, as the interest rates on the long-term debt are variable and the rates are based on market interest rates (bank's prime rate) after consideration of default and credit risk (using Level 2 inputs).

Future Aggregate Maturities

As of ~~March 31,~~June 30, 2023, future aggregate maturities of the Term Note and Financed Insurance Premium payables were as follows:


Years Ending December 31,	Years Ending December 31,	Amount		Years Ending December 31,	Amount
2023 (excluding the three months ended March 31, 2023)		$	3,298
2023 (excluding the six months ended June 30, 2023)				2023 (excluding the six months ended June 30, 2023)	$	2,204
2024	2024	5,000		2024	5,000
Total	Total	$	8,298	Total	$	7,204

Financed Insurance Premium

In July 2022, the Company renewed its corporate directors & officers and employment liability policies and entered into a new short-term commercial premium finance agreement with First Insurance Funding totaling $3,041 to be paid in eleven equal monthly payments, all of which accrue interest at a rate of 4.40%. In October 2022, the Company obtained additional general corporate liability policies and entered into an additional short-term commercial premium finance agreement with First Insurance Funding totaling $826 to be paid in eleven equal monthly payments, accruing interest at a rate of 6.80%. As of ~~March 31,~~June 30, 2023, the remaining principal balance on the combined financed insurance premiums was ~~$1,298.~~$204.

~~As of March 31,~~

In July 2023, the Company ~~was~~renewed its corporate directors & officers and employment liability policies and entered into a new short-term commercial premium finance agreement with First Insurance Funding totaling $927 to be paid in ~~compliance with all applicable covenants.~~eleven equal monthly payments, accruing interest at a rate of 8.29%.

Note 5. Commitments and Contingencies

During February 2023, the Company entered an agreement with a significant vendor to pay $3,000 of interest over 36 months with respect to past due payables. The present value of the future payments was expensed and included within interest expense, net on the condensed consolidated statements of operations for the ~~three~~six months ended ~~March 31,~~June 30, 2023.

Litigation

The Company is involved in legal proceedings from time to time arising in the normal course of business. Management, after consultation with legal counsel, believes that the outcome of these proceedings will not have a material impact on the Company’s financial position, results of operations, or liquidity.

In November 2021, two putative class action complaints were filed against us in the U.S. District Court for the Central District of California, Butala v. Owlet, Inc., et al., Case No. 2:21-cv-09016, and Cherian v. Owlet, Inc., et al., Case No. 2:21-cv-09293. Both complaints allege violations of the Securities Exchange Act of 1934 ("Exchange Act") against the Company and certain of its officers and directors on behalf of a putative class of investors who (i) purchased the Company’s common stock between March 31, 2021 and October 4, 2021 or (ii) held common stock in Sandbridge Acquisition Corporation (“SBG”) as of June 1, 2021 and were eligible to vote at SBG’s special meeting held on July 14, 2021. Both complaints allege, among other things, that the Company and certain of its officers and directors made false and/or misleading statements and failed to disclose certain information regarding the FDA’s likely classification of the Smart Sock product as a medical device requiring marketing authorization. The Court has consolidated the Butala and Cherian cases but has yet to appoint a lead plaintiff. The Company intends to vigorously defend itself against these claims, including by filing a motion to dismiss on behalf of itself and the named officers and directors.

Indemnification

In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors’ and officers’ insurance coverage that reduces its exposure and enables the

Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is immaterial.

Note 6. Stock-based Compensation

The Company has various stock compensation plans, which are more fully described in Part II, Item 8 "Financial Statements and Supplementary Data - Note 10 to the Consolidated Financial Statements - Share-based Compensation" in the 2022 Annual Report on Form 10-K. Under the 2021 Incentive Award Plan, the Company has the ability to grant options, stock appreciation rights, restricted stock, restricted stock units ("RSU"), performance stock units ("PRSU"), dividend equivalents, or other stock or cash-based awards to employees, directors, or consultants.

Option awards are generally granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. Options, RSU, and PRSU awards generally vest over a period of four years.

Stock-based Compensation Expense

Total stock-based compensation was recognized as follows (in thousands):


		Three Months Ended March 31,					Three Months Ended June 30,				Six Months Ended June 30,
		2023		2022			2023		2022		2023		2022
General and administrative	General and administrative	$	1,436	$	1544	General and administrative	$	1,461	$	1,864	$	2,897	$	3408
Sales and marketing	Sales and marketing	492		740		Sales and marketing	476		673		968		1,413
Research and development	Research and development	861		1,034		Research and development	707		720		1,568		1,754
Total stock-based compensation	Total stock-based compensation	$	2,789	$	3,318	Total stock-based compensation	$	2,644	$	3,257	$	5,433	$	6,575

During the three and six months ended ~~March 31,~~June 30, 2022, the Company capitalized ~~$18~~$16 and $33 of stock-based compensation attributable to internally developed software. There was no stock-based compensation capitalized during the three or six months ended ~~March 31,~~June 30, 2023.

As of ~~March 31,~~June 30, 2023, the Company had ~~$1,863~~$1,565 of unrecognized stock-based compensation costs related to non-vested options that will be recognized over a weighted-average period of ~~1.6~~1.4 years, ~~$11,079~~$8,503 of unrecognized stock-based compensation costs related to unvested RSUs that will be recognized over a weighted-average period of 2.4 years, and ~~$776~~$651 of unrecognized stock-based compensation costs related to unvested PRSUs that will be recognized over a weighted-average period of ~~1.9~~1.7 years.

Note 7. Convertible Preferred Stock and Common Stock Warrants

February 2023 Offering

On February 17, 2023 the Company entered into private placement investment agreements with certain investors, pursuant to which the Company issued and sold to the investors (i) an aggregate of 30,000 shares of the Company’s Series A convertible preferred stock, par value $0.0001 per share and (ii) warrants to purchase an aggregate of ~~110,204,066~~7,871,712 shares of the Company’s common stock, par value $0.0001 per share, (“February 2023 Warrants”) for an aggregate purchase price of $30,000.

The Series A convertible preferred stock is convertible into common stock at the option of the holder at any time after February 17, 2023 and ranks, with respect to dividend rights, rights of redemption and rights upon a liquidation event, (i) senior to the common stock and all other classes or series of equity securities of the Company established after February 17, 2023, unless such shares or equity securities expressly provide that they rank in parity with or senior to the Series A convertible preferred stock with respect to dividend rights, rights of redemption or rights upon a liquidation event, (ii) on parity with each class or series of equity securities of the Company established after the February 17, 2023, the terms of which expressly provide that it ranks on parity with the Series A convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event and (iii) junior to each class or series of equity securities of the Company established after February 17, 2023, the terms of which expressly provide that it ranks senior to the Series A convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event. ~~Holders~~Except as otherwise provided in the certificate of designation relating to the Series A convertible preferred stock or as required by law, holders of shares of Series A convertible preferred stock are entitled to vote with the holders of shares of ~~Common Stock~~common stock (and any other class or series that may similarly be entitled to vote with the holders of common stock) on an as-converted to common stock basis at any annual or special meeting of stockholders of the Company, and not as a separate ~~class, except as required by Delaware law.~~class.

At any time from and after February 17, 2028, the holders of at least a majority of the then outstanding shares of Series A convertible preferred stock may specify a date and time or the occurrence of an event by vote or written consent that all, and not less than all, of the outstanding shares of Series A preferred stock will automatically be: (i) converted into shares of common stock at a conversion rate of ~~2,040.8163~~145.7726 per share (the "Conversion Rate"), (ii) subject to certain exceptions and limitations, redeemed for an amount per share of Series A preferred stock equal to the liquidation preference of one thousand dollars per share, plus all accrued or declared but unpaid dividends as of the redemption date and time or (iii) a combination of the foregoing.

A Preferred Stock as would have been payable had all such shares been converted to common stock immediately prior to the liquidation event, plus, in each case, the aggregate amount of all declared but unpaid dividends thereon to the date of final distribution to the holders of Series A Preferred Stock.

Each of the February 2023 Warrants sold in the private placement offering is exercisable for one share of common stock at an exercise price of ~~$0.333~~$4.66 per share, is immediately exercisable, and will expire on February 17, 2028. None of the warrants have been exercised as of ~~March 31,~~June 30, 2023. As the February 2023 Warrants could require cash settlement in certain scenarios, the warrants were classified as liabilities upon issuance and were initially recorded at an aggregate estimated fair value of $26,133. The total proceeds from the offering were first allocated to the liability classified warrants, based on their fair values, with the residual $3,867 allocated to the Series A convertible preferred stock. The Series A convertible stock will accrete to its redemption value, starting from the issuance date to the date at which the shares become redeemable on February 17, 2028. Accretion will be recorded as a deemed dividend.

The Company incurred ~~$2,413~~$1,963 of issuance costs related to the offering, of which $295 were ~~accrued but not yet~~ paid as of ~~March 31,~~June 30, 2023. Issuance costs allocated to the preferred stock of ~~$311~~$253 were recorded as a reduction to ~~paid-in capital.~~the Series A preferred stock. Issuance costs allocated to the liability classified warrants of ~~$2,102~~$1,710 were recorded as an expense within general and administrative expenses. In connection with the issuance of these interim statements we have updated the classification of the preferred stock issuance costs incurred during the three months ended March 31, 2023 from a reduction of APIC to a reduction of the preferred stock carrying amount.

SBG Common Stock Warrants

As a result of the merger completed with Sandbridge Acquisition Corporation ("SBG") on July 15, 2021 (the "Merger"), the Company continues to record liabilities for warrants issued by SBG prior to the Merger.

Pursuant to the SBG initial public offering, SBG sold ~~23,000,000 units. Each unit consisted~~warrants to purchase an aggregate of ~~one share~~821,428 shares of ~~Class A~~the Company’s common stock ~~and one-half~~at a price of ~~one redeemable warrant~~$161.00 per share (“SBG Public Warrants”). ~~Each whole SBG Public Warrant entitles the holder to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment.~~ Following the closing of the Initial Public Offering on September 17, 2020, the Company completed the sale of ~~6,600,000~~ warrants ~~(the “SBG Private Placement Warrants”)~~to purchase an aggregate of 471,428 shares of the Company’s common stock at a price of $161.00 per share in a private placement to Sandbridge Acquisition Holdings ~~LLC.~~LLC (the “SBG Private Placement Warrants”). Together, the SBG Public Warrants and SBG Private Placement Warrants are referred to as the "SBG Common Stock Warrants."

~~SBG Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade.~~ The SBG Public Warrants became exercisable 12 months from the closing of the Initial Public Offering. The SBG Common Stock Warrants will expire five years after the completion of the Merger or earlier upon redemption or liquidation. ~~As a result of the Merger, both the 11,500,000 Public Warrants and 6,600,000 Private Placement Warrants are redeemable for shares of Common Stock.~~

See Part II, Item 8 "Financial Statements and Supplementary Data - Note 3 to the Consolidated Financial Statements - Merger" in the 2022 Annual Report on Form 10-K for the year ended December 31, 2022 (the "Form 10-K") for more information.

The following table summarizes issuable shares of the Company's common stock based on warrant activity for the ~~three~~six months ended ~~March 31,2023:~~June 30, 2023:


		Outstanding December 31, 2022	Warrants Issued	Warrants Exercised	Outstanding March 31, 2023		As of December 31, 2022	Shares Issuable by New Warrants	Shares Purchased by Exercise	As of June 30, 2023
SBG Public Warrants	SBG Public Warrants	11,500,000	—	—	11,500,000	SBG Public Warrants	821,428	—	—	821,428
SBG Private Placement Warrants	SBG Private Placement Warrants	6,600,000	—	—	6,600,000	SBG Private Placement Warrants	471,428	—	—	471,428
February 2023 Warrants	February 2023 Warrants	—	110,204,066	—	110,204,066	February 2023 Warrants	—	7,871,712	—	7,871,712
SVB Warrants (Note 4)	SVB Warrants (Note 4)	—	150,000	—	150,000	SVB Warrants (Note 4)	—	10,714	—	10,714
Total	Total	18,100,000	110,354,066	—	128,454,066	Total	1,292,856	7,882,426	—	9,175,282

Note 8. Fair Value Measurements

The following table presents information about the Company's assets and liabilities measured and reported in the financial statements at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.

March 31, 2023
Level 1 Level 2 Level 3 Balance
Assets:
Money market funds $ 23,963 $ — $ — $ 23,963
Total assets $ 23,963 $ — $ — $ 23,963
Liabilities:
SBG Public Warrants $ 445 $ — $ — $ 445
SBG Private Placement Warrants — 255 — 255
February 2023 Warrants — — 24,245 24,245
Total liabilities $ 445 $ 255 $ 24,245 $ 24,945
December 31, 2022
Level 1 Level 2 Level 3 Balance
Assets:
Money market funds $ 11,070 $ — $ — $ 11,070
Total assets $ 11,070 $ — $ — $ 11,070
Liabilities:
SBG Public Warrants $ 460 $ — $ — $ 460
SBG Private Placement Warrants — 264 — 264
Total liabilities $ 460 $ 264 $ — $ 724


	June 30, 2023
	Level 1		Level 2		Level 3		Balance
Assets:
Money market funds	$	20,556	$	—	$	—	$	20,556
Total assets	$	20,556	$	—	$	—	$	20,556
Liabilities:
SBG Public Warrants	$	—	$	—	$	149	$	149
SBG Private Placement Warrants	—		—		86		86
February 2023 Warrants	—		—		26,339		26,339
Total liabilities	$	—	$	—	$	26,574	$	26,574

	December 31, 2022
	Level 1		Level 2		Level 3		Balance
Assets:
Money market funds	$	11,070	$	—	$	—	$	11,070
Total assets	$	11,070	$	—	$	—	$	11,070
Liabilities:
SBG Public Warrants	$	460	$	—	$	—	$	460
SBG Private Placement Warrants	—		264		—		264
Total liabilities	$	460	$	264	$	—	$	724

Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

The SBG Public Warrants and SBG Private Placement Warrants as of ~~March 31,~~June 30, 2023 are ~~also included within~~presented in Level 13 of the fair value ~~hierarchy because they~~hierarchy. On June 15, 2023, the Company received notice from the New York Stock Exchange (the “NYSE”) that the NYSE had halted trading in the SBG Public Warrants due to the low trading price of those warrants. On June 16, 2023, the NYSE provided written notice to the Company and publicly announced that NYSE Regulation had determined to commence proceedings to delist the SBG Public Warrants and that such warrants were no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual. As such, these instruments are no longer valued using quoted market ~~prices. The SBG Private Placement Warrants are included within Level 2 of the fair value hierarchy as the Company determined that~~prices and correspondingly, the SBG Private Placement Warrants ~~are economically equivalent to the SBG Public Warrants and estimated the fair value of the SBG Private Placement Warrants~~can no longer be valued based on ~~the~~a quoted market price of the SBG Public Warrants. The Company measured the fair value of both the SBG Public Warrants and the SBG Private Placement Warrants as of June 30, 2023, using the Black-Scholes option pricing model with the following assumptions:


SBG Common Stock Warrants - Black-Scholes Inputs	June 30, 2023
OWLT stock price	$	4.76
Exercise price of warrants	$	161.00
Term in years	3.04
Risk-free interest rate	4.48		%
Volatility	90.00		%

The February 2023 Warrants are presented as Level 3 measurements, relying on unobservable inputs reflecting the Company's own assumptions. Level 3 measurements, which are not based on quoted prices in active markets, introduce a higher degree of subjectivity and may be more sensitive to fluctuations in stock price, volatility rates, and U.S. Treasury Bond rates.

The Company measured the fair value of the February 2023 Warrants at issuance and again as of ~~March 31,~~June 30, 2023, using the Black-Scholes option pricing model with the following assumptions:

1416


February 2023 Warrants - Black-Scholes Inputs	February 2023 Warrants - Black-Scholes Inputs	February 17, 2023			March 31, 2023			February 2023 Warrants - Black-Scholes Inputs	February 17, 2023			June 30, 2023
OWLT stock price	OWLT stock price	$	0.341		$	0.324		OWLT stock price	$	4.78		$	4.76
Exercise price of warrants	Exercise price of warrants	$	0.333		$	0.333		Exercise price of warrants	$	4.66		$	4.66
Term in years	Term in years	5.00			4.88			Term in years	5.00			4.63
Risk-free interest rate	Risk-free interest rate	4.10		%	3.61		%	Risk-free interest rate	4.10		%	4.20		%
Volatility	Volatility	85.00		%	85.00		%	Volatility	85.00		%	90.00		%

The following table presents a reconciliation of the Company’s SBG Public Warrants, SBG Private Placement Warrants, and February 2023 Warrants (together, the "Level 3 Warrants") measured at fair value on a recurring basis as of ~~March 31,~~June 30, 2023:

There were no transfers between Level 1 and Level 2 in the periods reported. ~~There~~The SBG Public Warrants and SBG Private Placement Warrants were ~~no transfers~~transferred into ~~or out of~~ Level 3 in the period ~~reported.~~reported, as discussed above.

The Company measured the fair value of the SVB Warrants (see Note 4) at issuance as of March 27, 2023, using the Black-Scholes option pricing model with the following assumptions:


SVB Warrants - Black-Scholes Inputs	March 27, 2023
OWLT stock price	$	~~0.330~~4.62
Exercise price of warrants	$	~~0.380~~5.32
Term in years	12.00
Risk-free interest rate	3.60		%
Volatility	85.00		%

1517

Note 9. Net Loss Per Share Attributable to Common Stockholders

Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Under the two-class method, net loss is attributed to common stockholders and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.

The Company considers its convertible preferred stock to be participating securities. Under the two-class method, the net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holders of the Company’s convertible preferred stock do not have a contractual obligation to share in the Company’s losses.

The following table presents the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):


		Three Months Ended March 31,					Three Months Ended June 30,				Six Months Ended June 30,
		2023		2022			2023		2022		2023		2022
Numerator:	Numerator:					Numerator:
Net loss and comprehensive loss	Net loss and comprehensive loss	$	(11,867)	$	(28,758)	Net loss and comprehensive loss	$	(8,467)	$	(11,718)	$	(20,334)	$	(40,476)
Accretion on Series A convertible preferred stock	Accretion on Series A convertible preferred stock	(653)		—		Accretion on Series A convertible preferred stock	(1,326)		—		(1,979)		—
Net loss attributable to common stockholders (1)	Net loss attributable to common stockholders (1)	$	(12,520)	$	(28,758)	Net loss attributable to common stockholders (1)	$	(9,793)	$	(11,718)	$	(22,313)	$	(40,476)
Denominator:	Denominator:					Denominator:
Weighted-average common shares used in computed net loss per share attributable to common stockholders basic and diluted	Weighted-average common shares used in computed net loss per share attributable to common stockholders basic and diluted	113,545,429		110,384,313		Weighted-average common shares used in computed net loss per share attributable to common stockholders basic and diluted	8,213,247		7,915,156		8,162,102		7,899,959
Net loss per share attributable to common stockholders basic and diluted	Net loss per share attributable to common stockholders basic and diluted	$	(0.11)	$	(0.26)	Net loss per share attributable to common stockholders basic and diluted	$	(1.19)	$	(1.48)	$	(2.73)	$	(5.12)

(1) For the three and six months ended ~~March 31,~~June 30, 2023, the Company did not allocate its net loss to participating convertible preferred stock as those shares are not obligated to share in the losses of the Company. There were no shares of convertible preferred stock outstanding during the three or six months ended ~~March 31,~~June 30, 2022.

The following table summarizes the common stock equivalents of potentially dilutive outstanding securities ~~were~~ excluded from the computation of diluted net loss per share due to their anti-dilutive effect:


		As of March 31,	As of March 31,		As of June 30,	As of June 30,
		2023	2022		2023	2022
Stock options	Stock options	7,418,570	9,866,965	Stock options	473,240	665,117
RSUs	RSUs	5,117,168	6,557,326	RSUs	299,646	482,987
PRSUs	PRSUs	1,222,526	1,842,105	PRSUs	79,803	131,578
ESPP shares committed	ESPP shares committed	333,447	234,133	ESPP shares committed	28,721	17,849
Common stock warrants	Common stock warrants	128,454,066	18,100,000	Common stock warrants	9,175,289	1,292,857
Convertible preferred stock	Convertible preferred stock	61,224,489	—	Convertible preferred stock	4,373,178	—
Total	Total	203,770,266	36,600,529	Total	14,429,877	2,590,388

The Company’s ~~2,807,500~~200,536 unvested earnout shares, described in Part II, Item 8 "Financial Statements and Supplementary Data - Note 11 to the Consolidated Financial Statements - Common Stock Warrants and Earnout

Shares" in the 2022 Form 10-K, were excluded from the calculation of basic and diluted per share calculations as the vesting conditions have not yet been met as of ~~March 31,~~June 30, 2023.

Note 10. Segments

The Company operates as a single operating segment. The Company’s chief operating decision maker manages the Company's operations on a consolidated basis for purposes of allocating resources, making operating decisions, and evaluating financial performance. Since the Company operates in one operating segment, all required financial segment information can be found in these consolidated financial statements.

Revenue by geographic area is based on the delivery address of the customer and is summarized as follows (in thousands):


		Three Months Ended March 31,					Three Months Ended June 30,				Six Months Ended June 30,
		2023		2022			2023		2022		2023		2022
United States	United States	$	9,543	$	18,712	United States	$	11,834	$	15,876	$	21,377	$	34,589
International	International	1,193		2,826		International	1,254		2,472		2,447		5,298
Total revenues	Total revenues	$	10,736	$	21,538	Total revenues	$	13,088	$	18,348	$	23,824	$	39,887

Other than the United States, no individual country exceeded 10% of total revenues for ~~either of~~ the three or six months ended ~~March 31,~~June 30, 2023 and ~~March 31,~~June 30, 2022.

The Company’s long-lived assets are composed of property and equipment and right of use assets, net, and are summarized by geographic area as follows as of (in thousands):


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
United States	United States	$	2,185	$	2,615	United States	$	1,813	$	2,615
International	International	577		753		International	435		753
Total long-lived assets, net	Total long-lived assets, net	$	2,762	$	3,368	Total long-lived assets, net	$	2,248	$	3,368

Note 11. New Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In June 2016, the Financing Accounting Standards Board ("FASB") issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and has since released various amendments including ASU No. 2019-04 and ASU No. 2022-02. The guidance modifies the measurement of expected credit losses on certain financial instruments. The Company adopted ASU 2016-13 for the ~~three~~six months ended ~~March 31,~~June 30, 2023. The impact of adoption was immaterial.

1719

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included elsewhere in this Report and in “Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Form 10-K”). Certain statements we make under this Item 2 constitute “forward-looking statements” under the Reform Act. See “Cautionary Note Regarding Forward-Looking Statements” before Part I of this Report. You should consider our forward-looking statements in light of the risks discussed in our unaudited condensed consolidated financial statements, related notes and other financial information appearing elsewhere in this Report, the "Risk Factors" section of our Form 10–K and this Report, and our other filings with the SEC.

Overview

Our mission is to empower parents with the right information at the right time, to give them more peace of mind and help them find more joy in the journey of parenting. Our digital parenting platform aims to give parents real-time data and insights to help parents feel calmer and more confident. We believe that every parent deserves peace of mind and the opportunity to feel their well-rested best. We also believe that every child deserves to live a long, happy, and healthy life, and we are working to develop products to help facilitate that belief.

Components of Operating Results

Revenues

We recognize revenue primarily from products and the associated mobile applications. Revenues are recognized when control of goods and services is transferred to customers in an amount that reflects the consideration expected to be received by us in exchange for those goods and services. Substantially all of the Company's revenues were derived from product sales.

Cost of Revenues

Cost of revenues consists of product costs, including contract manufacturing, shipping and handling, depreciation and amortization relating to tooling and manufacturing equipment and software, warranty replacement, fulfillment costs, warehousing, hosting, and reserves for excess and obsolete inventory.

Operating Expenses

General and Administrative. General and administrative expenses consist primarily of salaries, benefits, stock-based compensation, and bonuses for finance and accounting, legal, human resources and administrative executives and employees; third-party legal, accounting, and other professional services; corporate travel and entertainment; depreciation and amortization of property and equipment; and facilities rent.

Sales and Marketing. Sales and marketing expenses consist primarily of salaries, commissions, benefits, stock-based compensation, ~~commissions,~~ and bonuses for sales and marketing employees and contractors; third-party marketing expenses such as social media and search engine marketing; email marketing and print marketing.

Research and Development. Research and development expenses consist primarily of salaries, benefits, stock-based compensation, and bonuses for employees and contractors engaged in the design, development, maintenance and testing of our products and platforms.

Other Income (Expense)

Interest Expense, Net. Interest expense consists of interest incurred on our outstanding borrowings, including interest incurred on past due payables with one of our vendors as described in Note 5 to the condensed consolidated financial statements, and amortization of deferred financing costs. Interest expense is presented net of interest income earned on our money market account.

Common Stock Warrant Liability Adjustment. Mark to market adjustment to recognize the change in fair value of common stock warrant liabilities in other income (expense).

Other Income (Expense), Net. Other income (expense), net includes our net gain (loss) on foreign exchange transactions.

Income Tax Provision. Income tax provision consists primarily of U.S. federal and state income taxes related to the tax jurisdictions in which we conduct business.

1920

Results of Operations

The following table sets forth our results of operations for the periods indicated in millions (note that amounts within this Item 2 shown in millions may not sum due to rounding):


		For the Three Months Ended March 31,					For the Three Months Ended June 30,		For the Six Months Ended June 30,
			2023		2022				2023		2022		2023		2022
Revenues	Revenues		$	10.7	$	21.5		Revenues	$	13.1	$	18.3	$	23.8	$	39.9
Cost of revenues	Cost of revenues		6.6		12.8			Cost of revenues	7.9		11.7		14.4		24.5
Gross profit	Gross profit		4.2		8.8			Gross profit	5.2		6.6		9.4		15.4
Operating expenses:	Operating expenses:							Operating expenses:
General and administrative	General and administrative		8.9		10.3			General and administrative	6.1		9.5		15.0		19.8
Sales and marketing	Sales and marketing		3.4		11.6			Sales and marketing	3.1		9.7		6.4		21.4
Research and development	Research and development		2.9		8.5			Research and development	2.7		7.8		5.6		16.3
Total operating expenses	Total operating expenses		15.1		30.5			Total operating expenses	11.9		27.0		27.1		57.4
Operating loss	Operating loss		(11.0)		(21.7)			Operating loss	(6.7)		(20.4)		(17.7)		(42.1)
Other income (expense):	Other income (expense):							Other income (expense):
Interest expense, net	Interest expense, net		(2.8)		(0.2)			Interest expense, net	(0.1)		(0.2)		(2.9)		(0.4)
Common stock warrant liability adjustment	Common stock warrant liability adjustment		1.9		(6.9)			Common stock warrant liability adjustment	(1.6)		8.8		0.3		1.9
Other income (expense), net	Other income (expense), net		—		—			Other income (expense), net	(0.1)		0.1		(0.1)		0.1
Total other income (expense), net	Total other income (expense), net		(0.9)		(7.1)			Total other income (expense), net	(1.7)		8.7		(2.7)		1.6
Loss before income tax provision	Loss before income tax provision		(11.9)		(28.8)			Loss before income tax provision	(8.5)		(11.7)		(20.3)		(40.4)
Income tax provision	Income tax provision		0.0		0.0			Income tax provision	0.0		0.0		0.0		0.0
Net loss and comprehensive loss	Net loss and comprehensive loss		$	(11.9)	$	(28.8)		Net loss and comprehensive loss	$	(8.5)	$	(11.7)	$	(20.3)	$	(40.5)

Revenues


		For the Three Months Ended March 31,				Change					For the Three Months Ended June 30,				Change				For the Six Months Ended June 30,				Change
(dollars in millions)	(dollars in millions)	2023		2022		$		%		(dollars in millions)	2023		2022		$		%		2023		2022		$		%
Revenues	Revenues	$	10.7	$	21.5	$	(10.8)	(50.2	%)	Revenues	$	13.1	$	18.3	$	(5.3)	(28.7	%)	$	23.8	$	39.9	$	(16.1)	(40.3	%)

Revenues decreased by ~~$10.8~~$5.3 million, or ~~50.2%~~28.7%, from ~~$21.5~~$18.3 million for the three months ended ~~March 31,~~June 30, 2022 to ~~$10.7~~$13.1 million for the three months ended ~~March 31,~~June 30, 2023. The decrease was primarily due to lower sales of Owlet Sock products, impacted by retailers targeting lower ~~consumer sell-through~~inventory levels, ~~and~~reflecting macroeconomic conditions.

Revenues decreased by $16.1 million, or 40.3%, from $39.9 million for the six months ended June 30, 2022 to $23.8 million for the six months ended June 30, 2023. The decrease was primarily due to lower sales of Owlet Sock products, impacted by retailers targeting lower inventory levels, reflecting macroeconomic conditions. ~~The three~~Additionally, the six months ended ~~March 31,~~June 30, 2022 included the initial launch of the Dream Sock product and included significant sell-in sales of that new product across all channel ~~partners. Provisions for returns and chargeback allowances decreased significantly as compared to~~partners, which did not occur in the ~~same~~corresponding period in ~~the prior year, primarily due to the impact of the FDA Warning Letter.~~2023.

Cost of Revenues and Gross Profit

For the Three Months Ended March 31, Change
(dollars in millions) 2023 2022 $ %
Cost of revenues $ 6.6 $ 12.8 $ (6.2) (48.5 %)
Gross profit $ 4.2 $ 8.8 $ (4.6) (52.6 %)
Gross margin 38.7 % 40.7 %


	For the Three Months Ended June 30,						Change				For the Six Months Ended June 30,						Change
(dollars in millions)	2023			2022			$		%		2023			2022			$		%
Cost of revenues	$	7.9		$	11.7		$	(3.9)	(33.0	%)	$	14.4		$	24.5		$	(10.1)	(41.1	%)
Gross profit	$	5.2		$	6.6		$	(1.4)	(21.0	%)	$	9.4		$	15.4		$	(6.0)	(39.0	%)
Gross margin	40.0		%	36.1		%					39.4		%	38.6		%

Cost of revenues decreased by ~~$6.2~~$3.9 million, or ~~48.5%~~33.0%, from ~~$12.8~~$11.7 million for the three months ended ~~March 31,~~June 30, 2022 to ~~$6.6~~$7.9 million for the three months ended ~~March 31,~~June 30, 2023. The decrease was primarily due to the decrease in

product sales. Gross margin ~~decreased~~increased from ~~40.7%~~36.1% for the three months ended ~~March 31,~~June 30, 2022 to ~~38.7%~~40.0% for the three months ended ~~March 31,~~June 30, 2023 primarily due to ~~higher~~lower direct product ~~costs~~costs.

Cost of revenues decreased by $10.1 million, or 41.1%, from ~~cost inflation.~~$24.5 million for the six months ended June 30, 2022 to $14.4 million for the six months ended June 30, 2023. The decrease was primarily due to the decrease in product sales. Gross margin was relatively flat, increasing from 38.6% for the six months ended June 30, 2022 to 39.4% for the six months ended June 30, 2023.

General and Administrative


		For the Three Months Ended March 31,				Change					For the Three Months Ended June 30,				Change				For the Six Months Ended June 30,				Change
(dollars in millions)	(dollars in millions)	2023		2022		$		%		(dollars in millions)	2023		2022		$		%		2023		2022		$		%
General and administrative	General and administrative	$	8.9	$	10.3	$	(1.4)	(13.7	%)	General and administrative	$	6.1	$	9.5	$	(3.4)	(35.5	%)	$	15.0	$	19.8	$	(4.8)	(24.2	%)

General and administrative expense decreased by ~~$1.4~~$3.4 million, or ~~13.7%~~35.5%, from ~~$10.3~~$9.5 million for the three months ended ~~March 31,~~June 30, 2022 to ~~$8.9~~$6.1 million for the three months ended ~~March 31,~~June 30, 2023. The decrease was driven primarily by lower compensation expense, including share-based compensation, from reduced general and administrative headcount as a result of the restructuring actions taken during the fiscal year 2022. Additionally, the Company took cost saving measures to reduce spend on consulting services.

General and administrative expense decreased by $4.8 million, or 24.2%, from $19.8 million for the six months ended June 30, 2022 to $15.0 million for the six months ended June 30, 2023. The decrease was driven primarily by lower compensation expense, including share-based compensation, from reduced general and administrative headcount as a result of the restructuring actions taken during the fiscal year 2022. Additionally, the Company took cost saving measures to reduce spend on consulting services, but this was offset by incurred transaction costs relating to the February 2023 preferred stock offering.

Sales and Marketing


		For the Three Months Ended March 31,				Change					For the Three Months Ended June 30,				Change				For the Six Months Ended June 30,				Change
(dollars in millions)	(dollars in millions)	2023		2022		$		%		(dollars in millions)	2023		2022		$		%		2023		2022		$		%
Sales and marketing	Sales and marketing	$	3.4	$	11.6	$	(8.3)	(71.2	%)	Sales and marketing	$	3.1	$	9.7	$	(6.6)	(68.3	%)	$	6.4	$	21.4	$	(14.9)	(69.9	%)

Sales and marketing expense decreased by $6.6 million, or 68.3%, from $9.7 million for the three months ended June 30, 2022 to $3.1 million for the three months ended June 30, 2023. The decrease was driven by lower spend on digital advertising and retail channel marketing, as well as lower compensation expense associated with reduced headcount.

Sales and marketing expense decreased by ~~$8.3~~$14.9 million, or ~~71.2%~~69.9%, from ~~$11.6~~$21.4 million for the ~~three~~six months ended ~~March 31,~~June 30, 2022 to ~~$3.4~~$6.4 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023. The decrease was driven by a decrease in all sales and marketing spend, including lower compensation expense from reduced sales and marketing headcount. Additionally, the Company reduced spend on digital advertising and retail channel marketing spend.

Research and Development


		For the Three Months Ended March 31,				Change					For the Three Months Ended June 30,				Change				For the Six Months Ended June 30,				Change
(dollars in millions)	(dollars in millions)	2023		2022		$		%		(dollars in millions)	2023		2022		$		%		2023		2022		$		%
Research and development	Research and development	$	2.9	$	8.5	$	(5.7)	(66.2	%)	Research and development	$	2.7	$	7.8	$	(5.0)	(64.7	%)	$	5.6	$	16.3	$	(10.7)	(65.5	%)

Research and development expense decreased by ~~$5.7~~$5.0 million, or ~~66.2%~~64.7%, from ~~$8.5~~$7.8 million for the three months ended ~~March 31,~~June 30, 2022 to ~~$2.9~~$2.7 million for the three months ended ~~March 31,~~June 30, 2023. These decreases were primarily driven by lower compensation expense from reduced research and development headcount. Additionally, the Company took cost saving measures to reduce spend on consulting services.

Research and development expense decreased by $10.7 million, or 65.5%, from $16.3 million for the six months ended June 30, 2022 to $5.6 million for the six months ended June 30, 2023. These decreases were primarily driven by lower compensation expense from reduced research and development headcount. Additionally, the Company took cost saving measures to reduce spend on consulting services.

Other Income (Expense)


		For the Three Months Ended March 31,				Change					For the Three Months Ended June 30,				Change				For the Six Months Ended June 30,				Change
(dollars in millions)	(dollars in millions)	2023		2022		$		%		(dollars in millions)	2023		2022		$		%		2023		2022		$		%
Interest expense, net	Interest expense, net	$	(2.8)	$	(0.2)	$	(2.6)	1,144.2	%	Interest expense, net	$	(0.1)	$	(0.2)	$	(0.2)	74.4	%	$	(2.9)	$	(0.4)	$	(2.4)	567.6	%
Common stock warrant liability adjustment	Common stock warrant liability adjustment	$	1.9	$	(6.9)	$	8.8	(128	%)	Common stock warrant liability adjustment	$	(1.6)	$	8.8	$	(10.4)	(118.5	%)	$	0.3	$	1.9	$	(1.7)	(85.4	%)
Other income, net	Other income, net	$	—	$	—	$	(0.1)	NM		Other income, net	$	(0.1)	$	0.1	$	(0.1)	(206.3	%)	$	(0.1)	$	0.1	$	(0.2)	(171.6	%)

NM - Not meaningful

Interest expense ~~increased~~was steady, decreasing by ~~$2.6~~$0.2 million, from $0.2 million for the three months ended ~~March 31,~~June 30, 2022 to ~~$2.8~~$0.1 million for the three months ended ~~March 31,~~June 30, 2023.

For the three months ended June 30, 2023, we recognized a loss of $1.6 million as compared to a gain of $8.8 million for the same period in the prior year resulting from an increase in the fair value of common stock warrants outstanding.

Interest expense increased by $2.4 million, from $0.4 million for the six months ended June 30, 2022 to $2.9 million for the six months ended June 30, 2023. As noted in Part I. Item 1. Note 5. "Commitments and Contingencies" of this Report, the Company entered an agreement with a significant vendor to pay $3.0 million of

interest over 36 months with respect to past due payables. The present value of the future payments was expensed and included within interest expense, net on the condensed consolidated statements of operations for the ~~three~~six months ended ~~March 31,~~June 30, 2023.

For the ~~three~~six months ended ~~March 31,~~June 30, 2023, we recognized a gain of ~~$1.9~~$0.3 million as compared to a ~~loss~~gain of ~~$6.9~~$1.9 million for the same period in the prior year resulting from ~~a decrease~~an increase in the fair value of common stock warrants outstanding.

Liquidity and Capital Resources

We have historically funded our operations primarily with proceeds from issuances of our convertible preferred stock, issuances of our common stock, borrowings under our loan facilities, issuances of convertible promissory notes, and sales of our products and services. In connection with the Merger, the Company raised $133.9 million net proceeds, which combined with the sale of products and services funded our operations from the date of the Merger through the year ended December 31, 2022. As of December 31, 2022, we had cash and cash equivalents of $11.2 million.

stock (and any other class or series that may similarly be entitled to vote with the holders of common stock) on an as-converted to common stock basis at any annual or special meeting of stockholders of the Company, and not as a separate ~~class, except as required by Delaware law.~~class.

Subject to certain exceptions, upon the occurrence of a fundamental change, voluntary or involuntary liquidation, dissolution or winding-up of the Company, the Company will be required to pay an amount per share of Series A Preferred Stock equal to the greater of (i) one thousand dollars per share or (ii) the consideration per share of Series A Preferred Stock as would have been payable had all such shares been converted to common stock immediately prior to the liquidation event, plus, in each case, the aggregate amount of all declared but unpaid dividends thereon to the date of final distribution to the holders of Series A Preferred Stock.

Each of the February 2023 Warrants sold in the private placement offering is exercisable for one share of common stock at an exercise price of ~~$0.333~~$4.66 per share, is immediately exercisable, and will expire on February 17, 2028. None of the warrants have been exercised as of ~~March 31,~~June 30, 2023. As the February 2023 Warrants could require cash settlement in certain scenarios, the warrants were classified as liabilities upon issuance and were initially recorded at an aggregate estimated fair value of $26.1 million. The total proceeds from the offering were first allocated to the liability classified warrants, based on their fair values, with the residual $3.9 million allocated to the Series A convertible preferred stock. The Series A convertible stock will accrete to its redemption value, starting from the issuance date to the date at which the shares become redeemable on February 17, 2028. Accretion will be recorded as a deemed dividend.

The Company incurred ~~$2.4~~$2.0 million of issuance costs related to the offering, of which $0.3 million were ~~accrued but not yet~~ paid as of ~~March 31,~~June 30, 2023. Issuance costs allocated to the preferred stock of $0.3 million were recorded as a reduction to paid-in capital. Issuance costs allocated to the liability classified warrants of ~~$2.1~~$1.7 million were recorded as an expense within general and administrative expenses.

On March 10, 2023, Silicon Valley Bank ("SVB") was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. On March 12, 2023, the Secretary of the Treasury, the chair of the Federal Reserve Board and the chairman of the FDIC released a joint statement related to the FDIC's resolution of the SVB receivership, which provided that all depositors would have access to all their money starting March 13, 2023. As of the date of this Report, all cash deposited with SVB, now a division of First Citizens Bank and Trust Company, by the Company has been accessible by the Company.

Funding Requirements

Since inception, the Company has experienced recurring operating losses and generated negative cash flows from operations, resulting in an accumulated deficit of ~~$234.6~~$243.1 million as of ~~March 31,~~June 30, 2023. During the three months ended ~~March 31,~~June 30, 2023 and 2022, we had negative cash flows from operations of ~~$9.4~~$16.8 million and ~~$27.4~~$55.7 million, respectively. As of ~~March 31,~~June 30, 2023, we had ~~$24.8~~$24.7 million of cash on hand.

As the Company continues to address these financial conditions, management has undertaken the following actions:

•As described above, on February 17, 2023 the Company consummated a sale of newly issued preferred stock and warrants to purchase its common stock for aggregate gross proceeds of $30.0 million.

•As described in Note 4 to the financial statements presented in Item 1 of this Report, in March 2023 the Company further amended its financing arrangement with SVB, under which the principal payments on the term note will be deferred until September 2023. This most recent amendment also revised the financial covenants for future periods.

business, financial condition and results of operations could be materially adversely affected. We also could be required to seek funds through arrangements with partners or others that may require us to relinquish rights or jointly own some aspects of our technologies, products or services that we would otherwise pursue on our own.

Loan and Security Agreement with Silicon Valley Bank

On November 23, 2022, the Company entered into the Third Amended and Restated Loan and Security Agreement (the “LSA”) with Silicon Valley Bank. The LSA amended, restated and replaced in its entirety the prior Second Amended and Restated Loan and Security Agreement, dated April 22, 2020, and all prior amendments. On March 27, 2023, the Company entered into the first amendment to the LSA with Silicon Valley Bank, now a division of First Citizens Bank and Trust Company (the “SVB Amendment”), that (i) deferred certain payments of principal by the Company until September 1, 2023, (ii) had Silicon Valley bank waive certain stated events of default, (iii) to expand the eligibility of inventory and accounts that the Company can borrow against, (iv) to modify certain financial covenants required of the Company, and (v) certain other ~~revisions in the first amendment.~~revisions.

Line of Credit

The LSA provides for a $10.0 million revolving line of credit (the “SVB Revolver”) as of ~~March 31,~~June 30, 2023. The SVB Revolver is an asset-based lending facility subject to borrowing base availability, which is limited by specified percentages of eligible accounts receivable and eligible inventory. Borrowing base availability can be impacted based upon the period's eligible accounts receivable and eligible inventory, and may be significantly lower than the full $10.0 million line of credit. As of ~~March 31,~~June 30, 2023, borrowing base availability was ~~$7.1~~$8.4 million.

Term Loan

The LSA also provided for an $8.5 million term loan (the “Term Loan”), replacing the term loans made under the previous agreement, of which $7.0 million was outstanding as of ~~March 31,~~June 30, 2023. The Term Loan amortizes with equal monthly installments of $0.5 million and matures on October 1, ~~2024.~~2024 (the "Term Loan Maturity Date").

As of ~~March 31, 2023,~~the date of this Report, the Company was in compliance with all applicable ~~covenants.~~covenants under the LSA.

Financed Insurance Premium

In July 2022, the Company renewed its corporate directors & officers and employment liability policies and entered into a new short-term commercial premium finance agreement with First Insurance Funding totaling $3.0 million to be paid in eleven equal monthly payments, all of which accrue interest at a rate of 4.40%. In October 2022, the Company obtained additional general corporate liability policies and entered into an additional short-term commercial premium finance agreement with First Insurance Funding totaling $0.8 million to be paid in eleven equal monthly payments, accruing interest at a rate of 6.80%. As of ~~March 31,~~June 30, 2023, the remaining principal balance on the combined financed insurance premiums was ~~$1.3~~$0.2 million.

Cash Flows

The following table summarizes our cash flow (in millions):


		Three Months Ended March 31,					Six Months Ended June 30,
		2023		2022			2023		2022
Net cash used in operating activities	Net cash used in operating activities	$	(9.4)	$	(27.4)	Net cash used in operating activities	$	(16.8)	$	(55.7)
Net cash used in investing activities	Net cash used in investing activities	—		(0.7)		Net cash used in investing activities	—		(1.2)
Net cash provided by financing activities	Net cash provided by financing activities	22.9		1.8		Net cash provided by financing activities	30.3		(0.9)
Net change in cash and cash equivalents	Net change in cash and cash equivalents	$	13.5	$	(26.3)	Net change in cash and cash equivalents	$	13.5	$	(57.8)

Operating Activities

For the ~~three~~six months ended ~~March 31,~~June 30, 2023, net cash used in operating activities was ~~$9.4~~$16.8 million as compared to net cash used in operating activities of ~~$27.4~~$55.7 million in the prior year. The change in operating cash flows was primarily driven by a lower net loss and lower working capital usage. Lower working capital usage was driven by decreases in accounts receivable and inventory levels, as compared to increases in the prior year. These were partially offset by a larger decrease in accounts payable and accrued and other expenses as compared to the prior year.

Investing Activities

For the ~~three~~six months ended ~~March 31,~~June 30, 2023, the Company used substantially no cash for investing activities, as compared to ~~$0.7~~$1.2 million for the ~~three~~six months ended ~~March 31,~~June 30, 2022. The decrease in cash used for investing activities is primarily related to the prioritization of research and development projects in correlation with the restructuring actions taken during the fiscal year 2022.

Financing Activities

For the ~~three~~six months ended ~~March 31,~~June 30, 2023, net cash provided by financing activities ~~increased~~was $30.3 million as compared to ~~$22.9 million from $1.8~~cash used in financing activities of $0.9 million for the ~~three~~six months ended ~~March 31,~~June 30, 2022, primarily driven by the private placement offering of preferred shares in February 2023, partially offset by debt payments.

Critical Accounting Policies and Estimates

There have been no material changes from the critical accounting policies and estimates disclosed in our 2022 Annual Report on Form 10-K, other than policies disclosed in this Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item.

2527

Item 4. Controls and Procedures.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as such terms are defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to provide reasonable assurance that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of ~~March 31,~~June 30, 2023, the effectiveness of our disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of ~~March 31,~~June 30, 2023 due to the material weaknesses in our internal control over financial reporting described below.

Material Weaknesses in Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13(a)-15(f) and 15(d)-15(f) under the Exchange Act.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. The following material weaknesses in our internal control over financial reporting exist as of ~~March 31,~~June 30, 2023.

We did not design and maintain an effective control environment commensurate with our financial reporting requirements. Specifically, we did not maintain a sufficient complement of personnel with an appropriate degree of internal controls and accounting knowledge, experience, and training commensurate with our accounting and financial reporting requirements. This material weakness contributed to the following additional material weaknesses:

•We did not design and maintain effective controls over the segregation of duties related to journal entries. Specifically, certain personnel have the ability to both create and post journal entries within the Company’s general ledger system. This material weakness did not result in any adjustments to the consolidated financial statements.

•We did not design and maintain effective controls over the accounting for the accuracy and existence of inventory, nor controls which verified the completeness and accuracy of accrued liabilities. Each of these material weaknesses resulted in immaterial adjustments that were recorded as out-of-period adjustments within the year ended December 31, 2022.

•We did not design and maintain effective controls over the accounting for convertible preferred stock and warrant arrangements. Further, we did not design and maintain effective controls to verify the completeness and accuracy of sales returns and accrued sales tax. Each of these material weaknesses resulted in material adjustments to several account balances and disclosures in the consolidated financial statements as of and for the year ended December 31, 2019. The sales returns material weakness also resulted in immaterial adjustments to revenue and accrued and other expenses as of and for the year ended December 31, 2022.

•We did not design and maintain effective controls over IT general controls for information systems that are relevant to the preparation of our consolidated financial statements. Specifically, we did not design and maintain (i) program change management controls to ensure that IT program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized

2628

and implemented appropriately, (ii) user access controls to ensure appropriate segregation of duties and that adequately restrict user and privileged access to financial applications, programs, and data to appropriate Company personnel, (iii) computer operations controls to ensure that critical batch jobs are monitored, and data backups are authorized and monitored, and (iv) testing and approval controls for program development to ensure that new software development is aligned with business and IT requirements. This material weakness did not result in any adjustments to the consolidated financial statements.

Additionally, each of the material weaknesses described above could result in a misstatement of one or more account balances or disclosures that would result in a material misstatement to the interim or annual consolidated financial statements that would not be prevented or detected.

Remediation Plan

We have initiated a plan to remediate these material weaknesses. The remediation measures will be ongoing, and although not all inclusive, remediation measures include hiring additional accounting and financial reporting personnel and implementing additional policies, procedures and controls, all of which will result in future costs for the Company.

We have taken actions to improve our IT general controls, segregation of duties over journal entries controls, inventory controls, accrued liabilities, convertible preferred stock, warrant arrangements, sales returns and accrued sales tax controls. However, the material weaknesses will not be considered remediated until our remediation plan has been fully implemented, the applicable controls operate for a sufficient period of time, and we have concluded, through testing, that the newly implemented and enhanced controls are operating effectively.

Notwithstanding the above, our management believes that the consolidated financial statements included in this Report on Form 10-Q state fairly in all material respects our financial position, results of operations and cash flows for the periods presented.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended ~~March 31,~~June 30, 2023 that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

2729

PART II

Item 1. Legal Proceedings.

In the ordinary course of business we face various claims brought by third parties, and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property rights as well as claims relating to employment matters and the safety or efficacy of our products. Any of these claims could subject us to costly litigation, and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, may be inadequately capitalized to pay on valid claims, or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our business, financial condition and results of operations. Additionally, any such claims, whether or not successful, could damage our reputation and business.

In November 2021, two putative class action complaints were filed against us in the U.S. District Court for the Central District of California, the first captioned Butala v. Owlet, Inc., et al., Case No. 2:21-cv-09016, and the second captioned Cherian v. Owlet, Inc., et al., Case No. 2:21-cv-09293. Both complaints allege violations of the Securities Exchange Act of 1934 against the Company and certain of its officers and directors on behalf of a putative class of investors who: (a) purchased the Company’s common stock between March 31, 2021 and October 4, 2021; or (b) held common stock in SBG as of June 1, 2021, and were eligible to vote at SBG's special meeting held on July 14, 2021. Both complaints allege, among other things, that the Company and certain of its officers and directors made false and/or misleading statements and failed to disclose certain information regarding the FDA’s likely classification of the Owlet Smart Sock as a medical device requiring marketing authorization. The Court has consolidated the Butala and Cherian cases but has yet to appoint a lead plaintiff. The Company intends to vigorously defend itself against these claims, including by filing a motion to dismiss on behalf of itself and the named officers and directors.

Item 1A. Risk Factors.

In addition to the information contained in this Report, you should carefully consider the risk factors disclosed in our Form 10-K, which could materially affect our business, financial condition or results. Except as described below and elsewhere in this Report, there have been no material changes from the risk factors previously disclosed in our Form 10-K.

Our failure to meet the NYSE’s continued listing requirements could result in a delisting of our common stock.

Ifwe fail to satisfy the NYSE's continued listing requirements, the NYSE may take steps to delist our common stock. For example, in April 2023, we were notified by NYSE that we were not in compliance with Section 802.01B of the NYSE Listed Company Manual as the average global market capitalization of our common stock over a consecutive 30 trading-day period and, at the same time, our last reported stockholders’ equity were each less than $50 million. ~~As permitted under the NYSE rules,~~In May 2023, we ~~plan to submit~~submitted a business plan advising the NYSE of the definitive ~~action~~actions we ~~have~~had taken ~~or are~~as of the date of that submission and were planning on taking ~~that would~~in order to bring us into compliance with NYSE continued listing standards within 18 months of receipt of the NYSE Notification (the “Cure Period”). ~~The NYSE will review the plan and determine whether we have made a reasonable demonstration of our ability to regain compliance with the relevant standards within the Cure Period.~~ There can be no assurance that we will be able to achieve the ~~NYSE will agree that we have demonstrated~~actions identified in our ~~ability~~plan to regain compliance ~~with the relevant standards~~or that those actions will result in our market capitalization equaling or exceeding $50 million within the Cure ~~Period or,~~Period. Even if we regain compliance, there can be no assurance that we will be able to maintain compliance with these or any other NYSE listing requirements.

Delisting from the NYSE could make trading our common stock more difficult for investors, potentially leading to declines in our share price and liquidity. In addition, without a NYSE market listing, stockholders may have a difficult time getting a quote for the sale or purchase of our common stock, the sale or purchase of our common stock would likely be made more difficult and the trading volume and liquidity of our common stock could decline. Delisting from the NYSE could also result in negative publicity and could also make it more difficult for us to raise additional capital. The absence of such a listing may adversely affect the acceptance of our common stock as currency or the value accorded by other parties. If our common stock is delisted by the NYSE, our common stock may be eligible to trade on an over-the-counter quotation system, such as the OTCQB market, where an investor may find it more difficult to sell our common stock or obtain accurate quotations as to the market value of our common stock. We cannot assure you that our common stock, if delisted from the NYSE, would be eligible to be listed on another national securities exchange or quoted on an over-the counter quotation system.

Concentration of ownership among our existing directors, executive officers and principal stockholders may prevent new investors from influencing significant corporate decisions.

2830

Our directors, executive officers and holders of 5% or more of our capital stock and their respective affiliates beneficially own and/or have the right to acquire a significant amount of our common stock. As of June 30, 2023, these stockholders beneficially owned shares of our common stock and/or Series A convertible preferred stock that represented approximately 70.5% of the voting power of our capital stock. Accordingly, these stockholders will be able to influence us through this ownership position. Subject to any fiduciary duties owed to our other stockholders under Delaware law, these stockholders may be able to exercise significant influence over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions, and will have some control over our management and policies. Some of these persons or entities may have interests that are different from yours. For example, these stockholders may support proposals and actions with which you may disagree or which are not in your best interests. Our largest stockholders, Eclipse Ventures LLC and its affiliates (“Eclipse”), beneficially own approximately 38.75% of the voting power of our capital stock, which excludes voting power it may acquire upon exercise of warrants it acquired in the February 2023 private placement. For as long as Eclipse holds a significant amount of our Series A convertible preferred stock and common stock, it will be able to exert significant control over us. Eclipse may also determine to sell substantial amounts of our securities in one or more transactions, including to one or several private parties in negotiated transactions, which may result in those buyers subsequently being able to exert significant control over us.

This concentrated control, including that solely of Eclipse, may limit or preclude other stockholders’ ability to influence corporate matters for the foreseeable future, including the election of directors, amendments of our organizational documents, and any merger, consolidation, sale of all or substantially all of our assets, or other major corporate transaction requiring stockholder approval. In addition, these stockholders could use their voting influence to maintain our existing management and directors in office or support or reject other management and Board proposals that are subject to stockholder approval, such as amendments to our employee stock plans and approvals of significant financing transactions, and may prevent or discourage unsolicited acquisition proposals or offers for our capital stock that stockholders may believe are in their best interest.

Despite having received 510(k) clearance from the FDA for our prescription-only, BabySat pediatric monitor, such clearance does not ensure commercial success of this product, which will require us to implement processes, procedures and operations necessary to market and sell medical devices. We may not be successful in implementing these conditions, which could subject us to new risks.

In June 2023, we received 510(k) clearance from the FDA for BabySat, a prescription-only pulse oximeter indicated for use in measuring and displaying functional oxygen saturation of arterial hemoglobin and pulse rate and for spot-checking and/or continuous monitoring of well-perfused patients, greater than one month old up to 18 months old and weighing between 6 and 30 pounds, in the home environment. This is the first medical device marketing authorization we have received. In order to market and distribute a BabySat or other medical devices, we will need to modify certain of our internal business operations to ensure they comply with medical device requirements and to enable distribution of the product in accordance with its prescription-only marketing authorization. For example, in the direct-to-consumer model we utilize to distribute our current products, including the Dream Sock and Owlet Cam (as well as Smart Sock, in certain countries outside of the United States), consumers purchase our products directly from us or one of our retailers, and we will not be able to utilize this model to distribute BabySat in accordance with its-prescription-only marketing authorization. Though we are currently exploring a number of new distribution channels, including working with durable medical equipment distributors, healthcare institutions, and other healthcare payor and provider channels, we may not be successful in identifying, or implementing with our current resources, an appropriate distribution channel. Further, even though we have received FDA clearance for BabySat, we will still need to demonstrate the business and clinical rationale and justifications of this product in order for healthcare institutions and providers to be convinced of the need to prescribe it, and we may not be successful in these efforts.

We distribute our products into international markets and, in some of these jurisdictions, we will be required to obtain and maintain regulatory authorizations, including clearances, approvals, or other certifications, in order to commercialize certain of our products, which can be a lengthy and time-consuming process. If a foreign governmental authority were to require marketing authorization or similar certification for any product that we sell, we could be subject to international regulatory enforcement actions, and/or be required to cease selling, or recall, the product pending receipt of marketing authorization or similar certification from such other governmental authority or notified body, which could harm our financial results.

We currently sell the Smart Sock and Dream Sock in certain countries outside of the United States, and we expect certain of our pipeline products to be regulated as medical devices that will require marketing authorizations or certifications. In response to inquiries from the FDA and regulatory authorities in other jurisdictions regarding the marketing of the Smart Sock and Dream Sock, we have communicated our beliefs that such products are not medical devices that require medical device or similar marketing authorization or certification from such other regulatory

authorities or notified bodies. However, certain regulatory authorities have expressed that they do not agree with that conclusion and in some instances have required us to obtain marketing authorization or other certification to continue to sell the product. If we ultimately do not obtain marketing authorization or similar certification following such regulatory body’s review of any submissions we make for such products, we may be required to recall and/or cease distribution of those products until after marketing authorization or similar certification has been received.

For example, we have marketed and sold Dream Sock in Canada since January 2022. Health Canada, the regulatory authority responsible for the Canadian medical device market, initially asserted that the Dream Sock was a medical device that can no longer be sold in Canada unless a relevant license has been issued. In the second half of 2022, we responded with our position that the Dream Sock is not a medical device, and Health Canada has not affirmatively concluded that it agrees or disagrees with our position. If Health Canada does not agree with our position, we may be required to cease distribution of the product into the Canadian market and may be subject to enforcement action.

In addition, we have been marketing and selling the Smart Sock in the United Kingdom (“UK”). The Medicines and Healthcare products Regulatory Agency (“MHRA”), the regulatory authority responsible for the UK medical device market, has asserted that the Smart Sock requires certification by a notified body and subsequent registration as a medical device in the UK, and indicated it would allow us to continue to market the Smart Sock in the UK until the end of 2022. We requested an extension to that grace period and have continued to communicate with MHRA to provide updates regarding our continuing efforts to obtain marketing authorization, including our submission in June 2023 to our notified body, i.e., an independent organization accredited or designated by MHRA, for their review of Dream Sock with Health Notifications. The MHRA has responded to our communications but has not affirmatively extended the grace period for marketing Smart Sock. If the MHRA determines that we are not permitted to continue marketing Smart Sock notwithstanding our request to extend the grace period, we may have to cease distribution of the product in the UK and could be subject to enforcement action. Moreover, there is no assurance that we will be able to obtain in a timely manner the marketing authorization or certification for Dream Sock with Health Notifications, which we intend to market in the UK if and when registered.

The path to market varies among international jurisdictions and may require additional or different product testing than required to obtain FDA marketing authorization. Certifications or marketing authorizations from one foreign regulatory authority or notified body does not ensure certification or marketing authorization by any other foreign regulatory authority or notified body or by the FDA. If we fail to receive necessary certifications or marketing authorizations to commercialize our products in foreign jurisdictions on a timely basis, or at all, or if we later lose such certifications or marketing authorizations, our business, financial condition and results of operations could be adversely affected. Furthermore, foreign regulatory requirements may change from time to time, which could adversely affect our ability to market new products and services, or continue to market existing products and services, internationally.

Item 2. Unregistered Sales of Equity Securities, ~~and~~ Use of ~~Proceeds.~~Proceeds, and Issuer Purchases of Equity Securities.

Except as previously disclosed in our Current Report on Form 8-K filed with the SEC on February 21, 2023, there were no unregistered sales of equity securities for the three months ended March 31, 2023.None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

~~None.~~(a) Executive Change in Control Severance Plan

On August 11, 2023, the Compensation Committee of the Board of Directors (the “Committee”) adopted the Owlet, Inc. Executive Change in Control Severance Plan (the “CIC Severance Plan”). The following executives are eligible to participate in the CIC Severance Plan (“Plan Participants”): (i) each employee who is an “officer” of the Company within the meaning of Rule 16a-1(f) of the Exchange Act (“Tier 1 Participants”) and (ii) other employees at the level of Senior Vice President or above who have been designated by the CIC Severance Plan administrator as eligible to participate (“Tier 2 Participants”).

Plan Participants are eligible to receive compensation and benefits in the event of an involuntary termination of employment by the Company without cause, or a resignation from employment with the Company for good reason,

2932

which occurs within 3 months prior to, or 12 months after, the effective date of a change in control of the Company (a “Covered Termination”).

The CIC Severance Plan generally provides for the following payments and benefits upon a Covered Termination of a Plan Participant, which are in addition to any applicable accrued but unpaid obligations of the Company: (A) a lump sum payment equal to (i) 12 months (for Tier 1 Participants) or 6 months (for Tier 2 Participants) of the applicable Plan Participant’s annual base salary, plus (ii) the Plan Participant’s target bonus for, and prorated based on the number of days employed in, the year in which the Covered Termination occurs; (B) continued health coverage for a period of 12 months (for Tier 1 Participants) or 6 months (for Tier 2 Participants), or until the Plan Participant and their covered dependents become eligible for healthcare coverage under another employer’s plan(s), and (C) accelerated vesting of equity awards outstanding and unvested as of the date of the Covered Termination.

The CIC Severance Plan does not provide for any payments or benefits upon a Plan Participant’s termination for cause, voluntary resignation without good reason, or due to death or disability.

The foregoing description is only a summary and is qualified in its entirety by reference to the full text of the CIC Severance Plan, a copy of which is filed as Exhibit 10.5 to this Report and incorporated herein by reference.

All other terms and conditions under the respective officers’ employment agreements remain unchanged.

(b) None.

Item 6. Exhibits

Exhibit
Number

Description

Form

File No.

Exhibit

Filing Date

Exhibit
Number

Description

Form

File No.

Exhibit

Filing Date

2.1†

Merger Agreement, dated as of February 15, 2021, by and among the Registrant, Project Olympus Merger Sub, Inc. and Owlet Baby Care Inc.

8-K

001-39516

2.1

2/16/2021

2.1†

Merger Agreement, dated as of February 15, 2021, by and among the Registrant, Project Olympus Merger Sub, Inc. and Owlet Baby Care Inc.

8-K

001-39516

2.1

2/16/2021

3.1

Second Amended and Restated Certificate of Incorporation of Owlet, Inc.

S-4

333-254888

3.3

3/31/2021

3.1

Second Amended and Restated Certificate of Incorporation of Owlet, Inc.

S-4

333-254888

3.3

3/31/2021

3.2

Certificate of Designation of Series A Convertible Preferred Stock of Owlet, Inc.

8-K

001-39516

3.1

2/21/2023

3.2

Certificate of Designation of Series A Convertible Preferred Stock of Owlet, Inc.

8-K

001-39516

3.1

2/21/2023

3.3

Amended and Restated Bylaws of Owlet, Inc.

S-4

333-254888

3.4

3/31/2021

3.3

Second Amendment to the Second Amended and Restated Certificate of Incorporation of Owlet, Inc.

8-K

001-39516

3.1

7/7/2023

3.4

Amended and Restated Bylaws of Owlet, Inc.

S-4

333-254888

3.4

3/31/2021

4.1

Warrant Agreement, dated September 14, 2020, between Sandbridge Acquisition Corp. and Continental Stock Transfer & Trust Company.

8-K

001-39516

4.1

9/18/2020

4.1

Warrant Agreement, dated September 14, 2020, between Sandbridge Acquisition Corp. and Continental Stock Transfer & Trust Company.

8-K

001-39516

4.1

9/18/2020

4.2

Specimen Warrant Certificate.

S-1

333-24832

4.4

9/1/2020

4.2

Specimen Warrant Certificate.

S-1

333-24832

4.4

9/1/2020

4.3

Form of Warrant to Purchase Common Stock.

8-K

001-39516

4.1

2/21/2023

4.3

Form of Warrant to Purchase Common Stock.

8-K

001-39516

4.1

2/21/2023

10.1

Investment Agreement, dated February 17, 2023, by and among Owlet, Inc. and the investors listed on Schedule I thereto (Institutional Accounts).

8-K

001-39516

10.1

2/21/2023

10.2

Investment Agreement, dated February 17, 2023, by and among Owlet, Inc. and the investors listed on Schedule I thereto (Excluded Investors).

8-K

001-39516

10.2

2/21/2023

10.3

Amended and Restated Stockholders Agreement, dated February 17, 2023, by and among Owlet, Inc., Eclipse Ventures Fund, L.P., Eclipse Continuity Fund I, L.P. and Eclipse Early Growth Fund I, L.P.

8-K

001-39516

10.3

2/21/2023

10.4

First Amendment to the Third Amended and Restated Loan and Security Agreement, dated March 27, 2023, between Silicon Valley Bank, as bank lender, and Owlet, Inc. and its subsidiary, Owlet Baby Care, Inc., as borrowers.

8-K

001-39516

10.1

3/31/2023

10.5*

Owlet, Inc. Executive Change in Control Severance Plan

31.1*

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.1*

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**

Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.1**

Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*

Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.INS*

Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH*

Inline XBRL Taxonomy Extension Schema Document.

101.SCH*

Inline XBRL Taxonomy Extension Schema Document.

101.CAL*

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.CAL*

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF*

Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.DEF*

Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB*

Inline XBRL Taxonomy Extension Label Linkbase Document.

101.LAB*

Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE*

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

101.PRE*

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104*

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

104*

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*Filed herewith

**Furnished herewith.

†The annexes, schedules, and certain exhibits to this Exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.

3034

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Company Name

Date: ~~May 12,~~August 14, 2023	By:	/s/ Kurt Workman
	Name:	Kurt Workman
	Title:	~~President and~~ Chief Executive Officer
		(Principal Executive Officer)

Date: ~~May 12,~~August 14, 2023	By:	/s/ Kathryn R. Scolnick
	Name:	Kathryn R. Scolnick
	Title:	Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

3135

~~February 2023~~Level 3 Warrants

Balance as of December 31, 2022

Issuance of February 2023 Warrants

Change in fair value included within common stock warrant liability adjustment

~~(1,888)~~(283)

Balance as of ~~March 31,~~June 30, 2023

~~24,245~~26,574